Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Rises By 125.0%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 900 shares, a growth of 125.0% from the January 31st total of 400 shares. Based on an average trading volume of 13,500 shares, the short-interest ratio is currently 0.1 days.

Scinai Immunotherapeutics Price Performance

Shares of NASDAQ SCNI remained flat at $3.54 during midday trading on Friday. The stock had a trading volume of 1,969 shares, compared to its average volume of 14,584. The stock has a 50 day moving average of $3.47 and a 200 day moving average of $3.52. Scinai Immunotherapeutics has a 52-week low of $2.23 and a 52-week high of $8.92. The company has a market capitalization of $3.02 million, a PE ratio of -0.01 and a beta of 2.37. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.